Aging Population And Diabetes Will Expand Ocular Therapies
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 12 Analysts
Published
07 Aug 25
Updated
21 Aug 25
AnalystHighTarget's Fair Value
US$59.30
80.5% undervalued intrinsic discount21 Aug
US$11.59
1Y
24.6%7D
2.3%1Y
24.6%7D
2.3%